Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke - PubMed (original) (raw)

Clinical Trial

Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke

R von Kummer et al. Stroke. 1992 May.

Abstract

Background and purpose: There is little reported of the safety and efficacy of high-dose intravenous recombinant tissue plasminogen activator (alteplase) in combination with heparin anticoagulation in patients presenting with acute ischemic stroke.

Methods: Thirty-two patients with severe hemispheric stroke syndrome caused by angiographically proven middle cerebral artery and/or intracranial internal carotid artery occlusion were treated with 100 mg alteplase by intravenous infusion over 90 minutes within a mean +/- SD of 226 +/- 68 minutes after symptom onset. Recanalization was assessed by digital subtraction angiography in all patients immediately after treatment and by transcranial Doppler monitoring (n = 30) and/or a third angiogram (n = 5) 12-24 hours later.

Results: Complete or partial reperfusion was observed in 11 patients (34%) 90 minutes after the initiation of alteplase infusion and in 17 patients (53%) within 12-24 hours. Hemorrhagic infarction without clinical deterioration was detected by follow-up computed tomography in nine patients (28%). Fatal parenchymal hemorrhage occurred in three patients (9%) with huge middle cerebral artery infarcts. Serious hemorrhage from the puncture site occurred in two patients (6%). Good clinical outcome correlated with reperfusion (p less than 0.05) and the presence of grade 2 collateral blood flow (p less than 0.01).

Conclusions: When 100 mg of recombinant tissue plasminogen activator was given within the first 6 hours of acute stroke together with heparin the incidence of deleterious hemorrhage was less than 10%. Reperfusion and effective collateral blood flow seem to be two important factors associated with a small infarct volume and good clinical outcome.

PubMed Disclaimer

Cited by

Low-dose intra-arterial urokinase and aggressive mechanical clot disruption for acute ischemic stroke after failure of intravenous thrombolysis.
Yoon W, Park MS, Cho KH. Yoon W, et al. AJNR Am J Neuroradiol. 2010 Jan;31(1):161-4. doi: 10.3174/ajnr.A1746. Epub 2009 Aug 27. AJNR Am J Neuroradiol. 2010. PMID: 19713319 Free PMC article.
Thrombolytic Therapy in Acute Ischemic Stroke.
Furlan AJ, Katzan IL, Caplan LR. Furlan AJ, et al. Curr Treat Options Cardiovasc Med. 2003 Jul;5(3):171-180. doi: 10.1007/s11936-003-0001-4. Curr Treat Options Cardiovasc Med. 2003. PMID: 12777195
Superselective Intra-arterial Thrombolysis for Acute Cardioembolic Stroke in a Child with Idiopathic Dilated Cardiomyopathy. A Case Report.
Kitzmüller E, Gruber A, Marx M, Schlemmer M, Wimmer M, Richling B. Kitzmüller E, et al. Interv Neuroradiol. 1999 Jun 30;5(2):187-94. doi: 10.1177/159101999900500213. Epub 2001 May 15. Interv Neuroradiol. 1999. PMID: 20670510 Free PMC article.
Vascular occlusion sites determine differences in lesion growth from early apparent diffusion coefficient lesion to final infarct.
Fiehler J, Knudsen K, Thomalla G, Goebell E, Rosenkranz M, Weiller C, Röther J, Zeumer H, Kucinski T. Fiehler J, et al. AJNR Am J Neuroradiol. 2005 May;26(5):1056-61. AJNR Am J Neuroradiol. 2005. PMID: 15891159 Free PMC article.
Combined stent placement and thrombolysis in acute vertebrobasilar ischemic stroke.
Lin DD, Gailloud P, Beauchamp NJ, Aldrich EM, Wityk RJ, Murphy KJ. Lin DD, et al. AJNR Am J Neuroradiol. 2003 Oct;24(9):1827-33. AJNR Am J Neuroradiol. 2003. PMID: 14561611 Free PMC article.

Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke - PubMed (original) (raw)